BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30355313)

  • 1. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
    Son KB; Lopert R; Gleeson D; Lee TJ
    Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The high price of "free" trade: U.S. trade agreements and access to medicines.
    Lopert R; Gleeson D
    J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
    Son KB; Lee TJ
    Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-U.S. Free Trade Agreement in Korea.
    Son KB; Bae S; Lee TJ
    Int J Health Serv; 2019 Apr; 49(2):306-321. PubMed ID: 30626258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
    Castro A; Westerhaus M
    Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea.
    Choi N; Son KB; Byun J; Yang DW
    Global Health; 2022 Mar; 18(1):34. PubMed ID: 35313916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patenting and patent challenges in South Korea after introducing a patent linkage system.
    Son KB
    Global Health; 2022 Nov; 18(1):95. PubMed ID: 36371241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
    Jain D; Darrow JJ
    Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact on access to medicines from TRIPS-Plus: a case study of Thai-US FTA.
    Kessomboon N; Limpananont J; Kulsomboon V; Maleewong U; Eksaengsri A; Paothong P
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):667-77. PubMed ID: 20578557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
    Townsend B; Gleeson D; Lopert R
    Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health.
    Labonté R; Crosbie E; Gleeson D; McNamara C
    Global Health; 2019 May; 15(1):35. PubMed ID: 31088499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Past, present and future of pharmaceutical patents under Korea-US Trade Agreement.
    Shin YS
    Pharm Pat Anal; 2016 Jul; 5(4):237-48. PubMed ID: 27338849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
    Dougherty MP
    Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere.
    Baker BK
    PLoS Med; 2016 Mar; 13(3):e1001970. PubMed ID: 26954325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.